CGM 2024 Update

Continuous Glucose Monitor (CGM) systems have become instrumental for monitoring and management of diabetes. Since our last update in Spring 2023, there have been several updates regarding CGMs; most notably with the expansion of CGM coverage, Dexcom G6 to G7 transition, and the announcement of the Dexcom Stelo.

	Medicaid	Medicare	Commercial Insurances
Prior Authorization required	No	No	Possibly*
Coverage for T1 or T2 Diabetics	Both	Both	Both
Coverage based on insulin regimen	Dexcom: Covered regardless of patient on insulin Libre: Patient required to be on at least one (1) injection of insulin/day	Dexcom: Patient required to be on at least 1 injection of insulin/day Libre: Patient required to be on at least one (1) injection of insulin/day	Mealtime insulin patients or those with intensive insulin regimens (≥3 injections/day). Basal insulin regimen only currently not covered, but is anticipated to happen soon
Coverage based on at least one documented incidence of hypoglycemia	Covered regardless of patient on insulin	Covered regardless of patient on insulin	Covered regardless of patient on insulin
Coverage based on just GLP-1 medication regimen	No	No	Anticipated soon
Preferred CGM product per insurance	Dexcom or Libre	Dexcom or Libre	Dependent on individual plan
Where patients can obtain CGM device	Community Pharmacy	Community Pharmacy and/or Medical Equipment Supplier	Community Pharmacy

*Dependent on individual commercial insurance plan

Dexcom CGM Updates

As of December 2023, Dexcom has announced that they will be phasing out and discontinuing the Dexcom G6 system. With this change, their aim is to shift patients from the G6 over to the G7. Dexcom estimates it will take around one (1) year for this change to occur. Therefore, it is recommended for all new CGM prescriptions for Dexcom to be written for the Dexcom G7 system unless the patient is on an insulin pump that is only compatible with the Dexcom G6.

Most recently, on March 5, Dexcom announced the FDA approval of the first over-the-counter CGM, the Dexcom Stelo. Stelo is intended for anyone 18 years or older who does not use insulin or has problematic hypoglycemia. This product is anticipated to be available for purchase online in Summer 2024. Please see the chart on the next page for product comparisons and feel free to direct any questions or concerns to the GLIN IPA Pharmacy Team.

Product	Libre 14-day	Libre 2	Libre 3	Dexcom G6	Dexcom G7	Stelo
CGM or isCGM	isCGM	isCGM	CGM	CGM	CGM	CGM
Use in gestational DM#	Not FDA cleared	FDA cleared	FDA cleared	Not FDA cleared	FDA cleared	Not FDA cleared
Use in dialysis patients	Do not use	Do not use	Do not use	Do not use	Do not use	Do not use
Water Resistant	Yes	Yes	Yes	Yes	Yes	Yes
Warm up period	1 hour	1 hour	1 hour	2 hours	30 minutes	Unknown
Sensor life	14 days	14 days	14 days	10 days	10 days	15 days
Placement sites (Adult)	Back of upper arm	Back of upper arm	Back of upper arm	Abdomen	Back of upper arm	Back of upper arm
Bluetooth range	20 feet	20 feet	33 feet	20 feet	20 feet	Unknown
MARD^	9.4	9.3	7.9	9.0	8.2	Unknown
Low/High Alerts	No	Yes	Yes	Yes	Yes	No
Able to predict lows?	No	No	No	Yes	Yes	No
Compatible with insulin pumps?	No	Tandem t:slim X2™	Expected in the future	Omnipod® 5; Tandem t:slim X2™	Tandem t:slim X2™ (Expected in the near future for Omnipod® 5)	No
Interfering substances	Vitamin C Aspirin	Vitamin C Aspirin	Vitamin C Aspirin	>1g Acetaminophen Q6H Hydroxyurea (dose not specified)	>1g Acetaminophen Q6H Hydroxyurea (dose not specified)	Unknown
Ability to share with healthcare professionals*	Yes	Yes	Yes	Yes	Yes	Yes
Approved for use in making treatment decisions	Yes	Yes	Yes	Yes	Yes	Unknown
Prescription required?	Yes	Yes	Yes	Yes	Yes	No
Misc. Info	Reader has been discontinued			Being phased out within the next year as of December 2023.		Available for purchase online starting Summer 2024

CGM: Continuous Glucose Monitor
isCGM: Intermittently Scanning Continuous Glucose Monitor
T2DM: Type II Diabetes Mellitus
MARD: Mean Absolute Relative Difference

^The MARD measures the average difference between a device measurement and the reference measurement at normal to high glucose levels.

* Requires a compatible smart phone or the ability to upload reader device at home.

When a class I or II medical device is cleared, this means it has undergone a 510(k) submission, which FDA has reviewed and provided clearance, which means the manufacturer can demonstrate that their product is "substantially equivalent to another" predicate device.